🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

InSightec clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and China registers with InSightec as lead sponsor. Synced 26 Sep 2026
15Current trials
8Recruiting now
5Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

InSightec is the lead sponsor of 15 current clinical trials in our USA, UK and China registers. 8 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Atezolizumab, Cemiplimab and Doxorubicin. The most-studied condition is Essential Tremor.

ClinicalTrials.gov trials by status

  • Recruiting853%
  • Active, closed747%

Trials by phase

  • Not applicable960%
  • Observational427%
  • Phase 1/217%
  • Phase 317%
01

Clinical trials sponsored by InSightec

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
EMBRACE Tremor BiFUS
NCT06974916 · Essential Tremor
Not applicable Recruiting 2025-04 UK
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
NCT03671889 · Alzheimer Disease
Not applicable Recruiting 2018-09 USA
Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
NCT05386615 · Uterine Fibroid
Observational Recruiting 2016-02 USA, China
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
NCT04991831 · ClinicalTrials.gov ↗ · Tremor Associated With Tremor Dominant Parkinson's Disease
Observational Recruiting 2022-04 UK, USA
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858 · Brain Tumor, Non Small Cell Lung Cancer
Phase 3 Recruiting 2022-08 USA
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
NCT05539196 · ClinicalTrials.gov ↗ · Movement Disorders, Neurology, Parkinsons Disease
Observational Recruiting 2023-01 USA
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
NCT04197921 · ClinicalTrials.gov ↗ · Opioid-use Disorder, Substance Use Disorders
Not applicable Recruiting 2019-11 USA
A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects
NCT03028246 · ClinicalTrials.gov ↗ · Benign Centrally-Located Intracranial Tumors
Not applicable Recruiting 2017-02 USA
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease
NCT03319485 · Parkinson Disease
Not applicable Active, closed 2018-02 UK, USA
Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions
NCT03998657 · Prostate Cancer
Not applicable Active, closed 2019-12 USA
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT05630209 · Brain Tumor
Phase 1/2 Active, closed 2023-01 USA
Bilateral Treatment of Medication Refractory Essential Tremor
NCT04112381 · Essential Tremor
Not applicable Active, closed 2020-06 USA
MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
NCT00147056 · ClinicalTrials.gov ↗ · Brain Tumor
Not applicable Active, closed 2012-08 USA
Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)
NCT04728295 · ClinicalTrials.gov ↗ · Parkinson Disease
Not applicable Active, closed 2021-05 USA
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
NCT03100474 · ClinicalTrials.gov ↗ · Essential Tremor, Parkinson's Disease, Movement Disorders
Observational Active, closed 2016-12 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in InSightec trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in InSightec trials

16 conditions
Essential Tremor3Brain Tumor3Parkinson Disease2Movement Disorders2Tremor Associated With Tremor Dominant Parkinson's Disease1Alzheimer Disease1Prostate Cancer1Uterine Fibroid1Non Small Cell Lung Cancer1Neurology1Parkinsons Disease1Parkinson's Disease1Neuropathic Pain1Opioid-use Disorder1Substance Use Disorders1Benign Centrally-Located Intracranial Tumors1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA147
Clinical trials in UK32
Clinical trials in China11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Essential Tremor

SponsorTrials
Praxis Precision Medicines1

Sponsors with the most current trials registered for this condition.

06

Questions about InSightec trials

How many clinical trials does InSightec sponsor?

InSightec is the lead sponsor of 15 current trials on ClinicalTrials.gov in our USA, UK and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are InSightec trials recruiting?

Yes. 8 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is InSightec testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Atezolizumab (1), Cemiplimab (1), Doxorubicin (1), Nivolumab (1) and Pembrolizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.